Oral Proteins and Peptides Market Report 2024

This Oral Proteins And Peptides market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The oral proteins and peptides market size has grown exponentially in recent years. It will grow from $1.04 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 22.1%. The growth during the historical period can be attributed to the increasing prevalence of chronic diseases, heightened investments in biotechnology for developing oral protein-based treatments, a growing consumer preference for non-invasive therapies, expansion within the biopharmaceutical industry, and a rising emphasis on personalized medicine.

The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 22.4%. The growth during the forecast period can be attributed to a greater emphasis on patient-centric drugs, a rising geriatric population, increased healthcare spending, a growing need for cancer diagnostics, and a higher preference for oral medications. Key trends expected during this period include the development of new oral peptides with improved stability and efficacy, the integration of artificial intelligence in drug discovery for oral formulations, advancements in medical treatments, innovations in drug delivery technologies, and novel oral insulin formulations.

The expanding biopharmaceutical industry is expected to drive the growth of the oral proteins and peptides market in the future. This sector, part of the broader pharmaceutical industry, focuses on developing, producing, and commercializing drugs derived from biological sources. The growth of the biopharmaceutical industry is fueled by advancements in biotechnology, increased demand for personalized medicine, a rise in chronic diseases, and higher investment in research and development. Oral proteins and peptides offer the potential for non-invasive therapeutic delivery, improving patient compliance and reducing the need for injections. They can target specific diseases with enhanced stability and absorption in the digestive system. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that total biopharmaceutical production in Europe reached $384.2 billion (€340 billion) in 2022, a rise of about 4.95% from $366.3 billion (€323.95 billion) in 2021. Thus, the growth of the biopharmaceutical industry is contributing to the expansion of the oral proteins and peptides market.

Key companies in the oral proteins and peptides market are focusing on developing innovative products such as Oral Semaglutide to improve patient adherence and comfort. Oral Semaglutide represents a significant advancement in the field of oral proteins and peptides. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide was traditionally administered via injection for the treatment of type 2 diabetes and, more recently, obesity. For example, in January 2022, Novo Nordisk India, a healthcare company based in India, introduced the world’s first oral semaglutide, marking a major breakthrough in diabetes treatment. Previously available only in injectable form, this GLP-1 receptor analogue now offers a more convenient oral option for managing type 2 diabetes. This development not only revolutionizes diabetes care but also paves the way for future innovations in oral insulin formulations, potentially leading to more effective and patient-friendly treatment options.

In April 2023, Chiesi Farmaceutici S.p.a., an Italy-based pharmaceutical company, acquired Amryt Pharma Plc for an undisclosed sum. This acquisition allows Chiesi to leverage Amryt’s unique products and promising pipeline, bolstering its commitment to rare diseases and expanding its biopharmaceutical expertise. Amryt Pharma Plc, based in the UK, specializes in oral proteins and peptides.

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

North America was the largest region in the oral proteins and peptides market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral proteins and peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oral Proteins and Peptides refer to therapeutic proteins and peptides administered orally, typically in pills, capsules, or other ingestible formats. These biologically active molecules are designed to treat various medical conditions by leveraging their specific actions within the body.

The main drug types of oral proteins and peptides are linaclotide, calcitonin, insulin, plecanatide, and octreotide. The biological targets are guanylate cyclase-c (gc-c), insulin receptor, oxalate, and others, and the different mechanisms of action are receptor stimulation, substrate degradation, and others. It is used for various applications such as gastrointestinal disorders, bone disease, neurological disorders, diabetes, metabolic disorders, hormonal disorders, and cancer.

The oral proteins and peptides market research report is one of a series of new reports that provides oral proteins and peptides market statistics, including oral proteins and peptides industry global market size, regional shares, competitors with a oral proteins and peptides market share, detailed oral proteins and peptides market segments, market trends and opportunities, and any further data you may need to thrive in the oral proteins and peptides industry. This oral proteins and peptides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral proteins and peptides market consists of sales of protein supplements, peptide-based drugs, and therapeutic formulations designed for oral administration. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.